TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in area under time-concentration curve [AUC] of DTG and antimalarial drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maximum concentration [Cmax] of DTG and antimalarials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in time to maximum concentration [Tmax] for antimalarials and DTG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalization attributed to device infection
Endpoint domain: Adverse events/effects
Primary endpoint: Pelvic floor muscles function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of symptomatic RP attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cutaneous reaction score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Polymorphism frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low Back Pain Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean aortic valve pressure gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Adequate Cleansing Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute pain after cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with at least 25% reduction in vaginal cytology cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal pH <5.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline vaginal pH of at least 0.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Wound Appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants Reporting Local Reactogenicity Signs and Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: sexual performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: bacterial composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: neuromuscular response of lower limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Efficacy in hip fracture patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Major Molecular Response (MMolR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in Global Ocular Staining Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in eye color
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: feasibility
Endpoint domain: Resource use
Primary endpoint: Minimal in-scaffold lumen area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient emotional skills
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of interruptions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Radiographic bone changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Periodontal Attachment Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in psychological flexibility (AAQ-II)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in psychological flexibility (PQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of early onset Group B Streptococcus Disease
Endpoint domain: Mortality/survival
Primary endpoint: Change in Hamilton Anxiety Rating Scale (HAM-A) total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bacterial Diversity and Number of Bacteria Present in the Wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinical response to enzyme replacement therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Serum Creatinine Event of Grade 1 or Higher Over the Course of the Study
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Lumbar Spine Bone Mineral Density: Percent Change From Baseline to Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral Disinhibition/Risk Compensation: Number of Participants Reporting Unprotected Sex
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Degree of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in saliva nicotine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in breakpoint from two behavioral choice tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Addiction Research Center Inventory subjective abuse liability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the score of the Cellulite Severity Scale (CSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in biventricular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under The Concentration Versus Time Curve (AUC0-inf) of Single-dose Warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of Single-dose Warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time To Maximum Observed Concentration (Tmax) of Single-dose Warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biodistribution of 18F-AraG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kinetics of 18F-AraG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Embryos achieving blastocyst stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Hemodynamic performance of the bioprosthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in tissue oxygenation (StO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in local hemoglobin content (THC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maxim Tolerability Dose
Endpoint domain: Adverse events/effects
Primary endpoint: General stress level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: maternal DHA status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Grading of mottling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of IGF-I and II, sCD-163, VEGF, NGF and BDNF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of zinc transferred through breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Proportion of culture negative pulmonary TB patients in sputum at week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in clinical endpoints (cough clearance, chest x-ray clearance, fever remission, weight increase) up to 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants receiving specialty care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ovarian follicle damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change of anti-mullerian hormone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes of biological indicator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Skill Pages in SAGE-LEAF Accessed by a Participant
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Willingness to Recommend SAGE-LEAF to Other AD Caregivers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: System Usability Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximum Plasma Concentration (Cmax) of Agrylin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Agrylin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Half-life (T 1/2) of Agrylin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in Daily Pain Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Requiring Flexible Fiberoptic Bronchoscopy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Complete Response at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Clinician Administered PTSD Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-experiencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom Relief Speed (SRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom Relief Completeness (SRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time To Response (TTR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular-related deaths
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of treatment-related gastrointestinal acute adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of late gastrointestinal adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of treatment-related genitourinary acute adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of late genitourinary adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Asthma Control Questionnaire (ACQ(5)) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Virologic clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in baseline value of breath-by-breath gas analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of subjects with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in laboratory test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in electrocardiogram (ECG) data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Visual Analog Scale scores for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Epistaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life related to facial appearance
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: relief of burning during urination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in brain images
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of subjects achieving at least a 5% weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in muscle oxygenation after exercise/stretching training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in muscle interstitial pH after exercise/stretching training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in venoconstriction after exercise/stretching training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trans Epidermal Water Loss (TEWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Clinical Disease Control Rate (DCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term severity of asthma symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: plasma concentration of TMC435 after a single oral dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma concentration of TMC435 after a multiple oral dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine Consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Complete or Partial Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: knowledge test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of arrhythmia and conduction block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in geometric mean IELT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Seroprotection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Composite of Stroke, Systemic Embolism and Cardiovascular or Unexplained Death
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of Life-threatening Events, Including Device Embolization or Serious Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: mean reduction in HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Device or procedure related Serious Adverse Events (SAEs) and Unanticipated Adverse Device Effects (UADEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Birth of a living, viable child
Endpoint domain: Mortality/survival
Primary endpoint: Objective Clinical Response (CR or PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Without Progression at 4 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Microbiologically Confirmed Pulmonary Tuberculosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline in Total Exercise Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Values of unilateral pelvic tilts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Brain PCr/ATP Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Cognitive Function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of patients with brain malignancy
Endpoint domain: Mortality/survival
Primary endpoint: Cardiac involvement assessed by TTE imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac involvement assessed by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Polysomnographic measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ambulatory blood pressure monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness of medical care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of medical care
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Gingival Fissures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Resting postoperative pain at 24hr
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical activity (average steps per day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women using PHCs for antenatal, delivery and postnatal care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Useful Field of View Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with treatment limiting toxicities (TLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of AEs
Endpoint domain: Adverse events/effects
Primary endpoint: PCR unadjusted treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With at Least a 4-fold Rise in Meningococcal Antibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Concentrations (GMCs) of Diphtheria and Tetanus Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Concentrations (GMCs) of Pertussis Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 1 year disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Endogenous Glucose Production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Annual incidence of varicella-related hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: pain at 4 months after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Were Cured
Endpoint domain: Mortality/survival
Primary endpoint: Change in Heart Rate Variability at 4 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Mitochondrial Bioenergetics Measured by Basal Oxygen Consumption Rate at 4 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Blood Cytokines Measured by TNF α Levels at 4 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Acute performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to open airway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and severity of adverse events (AEs) and Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: 2-year Disease-free Survival (DFS)
Endpoint domain: Mortality/survival
Primary endpoint: Whole proteome depuration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Anxiety scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Difference in the urinary microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in postprandial discomfort severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation in PSQI (Pittsburgh Sleep Quality Index)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Time to HIV testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With Suicidal Ideation and Behavior as Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Developed Anti-erenumab Antibodies
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrence of AK lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monoyer chart result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Bacteriologic Failure or Relapse or Clinical Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Number of times in the toilet after colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Duration in the toilet after colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Recommended phase II dose of 9cUAB30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of 9cUAB30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of Gleason sum ≥7 tumours detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes